August 10, 2011

BELLUS Health reports results for second quarter ended June 30, 2011

Patient recruitment progressing for KIACTA(TM) Confirmatory Phase III Clinical Trial

LAVAL, QC, Aug. 10, 2011 /PRNewswire/ - BELLUS Health Inc. (TSX: BLU)
("BELLUS Health" or the "Company") reported today its financial results
for the second quarter ended June 30, 2011.

"Over the past several quarters, we have increasingly focused our
business model on our most promising products while reducing our burn
rate significantly," said Roberto Bellini, President and Chief
Executive Officer of BELLUS Health. "We made significant progress on
several fronts during the quarter. Patient recruitment for our lead
drug candidate KIACTA(TM) is progressing well and should be completed in
mid-2012. We also continued to expand the distribution footprint in
overseas markets for VIVIMIND(TM)."

Operating Highlights

        --  During the quarter, BELLUS Health and its strategic partner
            Celtic Therapeutics ("Celtic") continued recruitment for the
            global confirmatory phase III clinical trial for KIACTA(TM).
            The trial is designed to confirm the safety and efficacy of
            KIACTA(TM) in preventing renal function decline in patients
            diagnosed with AA amyloidosis. It will involve approximately
            230 patients enrolled from approximately 72 sites in 30
            countries. Patient recruitment is estimated to be completed in
            mid-2012. The confirmatory phase III clinical trial is the last
            key step before applications for regulatory approval for
            KIACTA(TM) can be filed. It is currently estimated that the
            trial will be completed in 2014.

        --  As previously announced, the Company recently signed licensing
            agreements for the marketing and distribution of
            VIVIMIND(TM) in Italy, Canada, Egypt, Pakistan, Iran and
            certain other Gulf States in the Middle East.

        --  The Company is currently seeking a potential partnership to
            pursue the development process of NRM8499, a prodrug of
            tramiprosate, for which a phase I clinical trial was completed
            in January 2011. Results of the trial showed a potential for
            pursuing NRM8499 for the treatment of Alzheimer's disease and
            demonstrated that NRM8499 was safe and well tolerated at the
            intended therapeutic dose.

        --  Since the second quarter of 2010, the Company has been
            implementing cost-reduction initiatives to reduce its
            fixed-cost base and extend its financial resources. These
            included the gradual reduction of the Company's head count by
            more than 75% as of June 30, 2011; early termination of the
            lease agreement for the Company's Laval, Quebec premises; and
            the reorganization of its international structure. According to
            management's current estimates, the Company's monthly burn rate
            is expected to decrease to approximately $350,000 in the

        --  On April 7, 2011, BELLUS Health issued 34,242,911 common shares
            from treasury at a price of approximately $0.125 per share to
            the landlord of its leased premises in Laval, Quebec, A.R.E.
            Quebec # 2, Inc. ("A.R.E.") as final payment for the deferred
            rent of approximately $4.3 million payable to A.R.E. The early
            termination of the lease is expected to result in annual
            savings of approximately $4.5 million for the Company,
            representing a total of approximately $43 million in aggregate
            savings over the remainder of the original lease term. The
            Company signed a new one-year lease that began on April 8, 2011
            at the same premises, for less space.

Summary of Financial Results

These financial results were prepared in accordance with International
Financial Reporting Standards ("IFRS"), as issued by the International
Accounting Standards Board. Comparative figures for 2010 have been
restated to conform to IFRS. Unless otherwise specified, all currency
figures reported in this news release are in Canadian dollars.

    |                          |Three-months ended|Three-months ended|
    |                          |     June 30, 2011|     June 30, 2010|
    |                          | (in thousands of dollars, except per|
    |                          |                           sharedata)|
    |Revenues                  |           719    |           536    |
    |Finance income            |         4,310    |         2,041    |
    |Research and development  |           341    |         2,243    |
    |expenses                  |                  |                  |
    |General and administrative|           789    |         2,815    |
    |expenses                  |                  |                  |
    |Net income (loss)         |         2,103    |        (3,667)   |
    |Basic earnings (loss) per |          0.01    |         (0.02)   |
    |share                     |                  |                  |
    |Diluted loss per share    |            -     |         (0.02)   |

The Company's full consolidated financial statements and accompanying
management's discussion and analysis for the three-month period ended
June 30, 2011, will be available shortly on SEDAR at and on the Company's web site at

        --  For the three-month period ended June 30, 2011, revenues
            amounted to $719,000, compared to $536,000 for the
            corresponding period the previous year. Revenues correspond
            mainly to the amortized portion of the US$10-million upfront
            payments received from Celtic pursuant to the asset sale and
            license agreement entered into with the Company in April of
            2010, as well as to revenues earned by the Company under the
            service agreement entered between the parties at the same

        --  For the three-month period ended June 30, 2011, finance income
            amounted to $4,310,000, compared to $2,041,000 for the
            corresponding period in the previous year. The increase in the
            current period is mainly attributable to a decrease in the fair
            value of the embedded derivative liability on the conversion
            option of the Company's 2009 Notes.

        --  Research and development expenses, before research tax credits
            and grants, amounted to $341,000 for the second quarter of
            2011, compared to $2,243,000 for the corresponding quarter of
            2010. The decrease is mainly attributable to the termination of
            the NC-503 (eprodisate) development program in the first half
            of 2010 as well as the reduction in the Company's workforce.

        --  General and administrative expenses were of $789,000 for the
            three-month period ended June 30, 2011, compared to $2,815,000
            for the same period the previous year. The decrease is mainly
            due to the Company's cost-reduction initiatives described under
            the Operating Highlights above.

        --  Net income for the second quarter of 2011 amounted to
            $2,103,000 ($0.01 per share), compared to a net loss of
            $3,667,000 ($0.02 per share) for the corresponding quarter in
            2010. The increase is mainly attributable to a decrease in the
            fair value of the embedded derivative liability on the
            conversion option of the Company's 2009 Notes in the amount of
            $4,247,000 for the three-month period.

        --  As at June 30, 2011, the Company had available cash and cash
            equivalents of $5,291,000.

About BELLUS Health

BELLUS Health is a development-focused health company concentrating on
the development of products that provide innovative health solutions
and address critical unmet medical needs. For further information on
BELLUS Health, please visit

Forward Looking Statements

Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may
constitute forward-looking statements. Such statements, based as they
are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown, many of which are
beyond BELLUS Health Inc.'s control. Such risks include but are not
limited to: the ability to obtain financing immediately in current
markets, the impact of general economic conditions, general conditions
in the pharmaceutical and/or nutraceutical industry, changes in the
regulatory environment in the jurisdictions in which the BELLUS Health
Group does business, stock market volatility, fluctuations in costs,
and changes to the competitive environment due to consolidation,
achievement of forecasted burn rate, and that actual results may vary
once the final and quality-controlled verification of data and analyses
has been completed. Consequently, actual future results may differ
materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance,
if any, on any forward-looking statements included in this news
release. These statements speak only as of the date made and BELLUS
Health Inc. is under no obligation and disavows any intention to update
or revise such statements as a result of any event, circumstances or
otherwise, unless required by applicable legislation or
regulation. Please see the Company's public fillings including the
Annual Information Form of BELLUS Health Inc. for further risk factors
that might affect the BELLUS Health Group and its business.